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Revisiting the issue: can the reading for serologic 
reactivity following 37% incubation be omitted? 
W.J. Judd, D. R. Fullen, E.A. Steiner, R.D. Davenport, and P. C. Knafl 
BACKGROUND: Omitting the 37°C reading from screening 
tests for unexpected antibodies results in failure to detect 
some Rh, K, and Jk agglutinins of potential significance 
(wanted positives). However, this measure avoids unwanted 
positive tests due to cold agglutinins. 
STUDY DESIGN AND METHODS: Using data from prior 
publications, actual risk calculations (ARCs) were made to 
predict the risk of eliminating the 37°C reading, 
pretransfusion direct antiglobulin test (DAT), and routine indi- 
rect antiglobulin crossmatch (IAT-XM). ARCs used the equa- 
tion: wanted positives missed x 0.34 (or 0.80) x 5 x percent 
antigen-positive, where 0.34 = percent of patients transfused 
(ARCs for 37°C reading and DAT); 0.80 = percent of 
crossmatched patients transfused (ARCs for IAT-XM); 5 = av- 
erage number of units transfused. Following elimination of 
the 37°C reading, the impact of this change on patient care 
was monitored. Antibody detection and identification data 
and transfusion reaction reports for 6 months after the 
change were reviewed. Recently transfused patients with 
new antibodies were evaluated for immune hemolysis by re- 
view of clinical and laboratory data. The findings were com- 
pared with those from the same dates of the preceding year. 
RESULTS The risk of transfusing incompatible blood by 
eliminating the DAT, IAT-XM, and 37°C reading is approxi- 
mately 1 :13,000, 1 :2,000, and 1 :2,400 units transfused, re- 
spectively. The cumulative risk from eliminating all three tests 
is approximately. 1 :1 ,OOO units. With respect to the 37°C 
reading, there were no differences between the pre-change 
and post-change study periods in the incidence of reported 
transfusion reactions or cases of immune hemolysis associ- 
ated with newly formed antibodies. However, unwanted posi- 
tive tests decreased from 162 to 61 following elimination of 
the 37°C reading. This represents a decrease of 20 percent 
in the number of samples requiring antibody identification an- 
nually. 
CONCLUSIONS: Eliminating the 37°C reading from 
pretransfusion antibody screening tests imposes less risk 
than omitting the routine IAT-XM, and it avoids the time and 
costs of evaluating unwanted positive tests, thus reducing ex- 
penditures and delays in patient care. 
n 1992, we reported that approximately 20 percent o f  
antibodies detected solely by reading for agglutina- 
t ion and hemolysis after 37°C incubation have Rh, K ,  I or Jk specificity.’ Because we encountered approxi- 
mately 25 patients with such antibodies annually, we 
elected at that t ime to  retain the 37°C reading as part o f  our 
screening procedure for unexpected antibodies. This test 
tube procedure is based o n  the low-ionic-strength saline 
(LISS) technique o f  Low and Messeter’ and utilizes two re- 
agent red cell (RBC) samples, 10-minute incubation at 37”C, 
and anti-IgG. 
We revisited our 1992 decision following a recent evalu- 
ation o f  the gel test (ID-Micro Typing System, Ortho-Clini- 
cal Diagnostics, Raritan, NJ).3 In th is  evaluation, the test 
failed to detect many examples o f  unwanted cold-reactive 
autoagglutinins and alloagglutinins found by  LISS. These 
antibodies are considered “unwanted” because their pres- 
ence rarely requires the selection o f  antigen-negative units 
for transfusion. However, the gel test missed three anti-K1 
and one anti-Jk” that reacted predominantly as agglutinins 
in LISS. By virtue o f  their specificity, we have considered 
these antibodies potentially significant, or “wanted,” with 
respect to the transfusion o f  antigen-positive RBCs. The 
term “wanted” is used here because the presence of such 
antibodies requires antigen-negative units to be selected for 
transfusion, and the units should also be compatible by the 
indirect antiglobulin t e ~ h n i q u e . ~  
Since other popular test tube methods, namely poly- 
ethylene glycol (PEG)5 and LISS additives, also missed ag- 
glutinins o f  wanted spe~if ic i t ies,~ we questioned the true 
ABBREVIATIONS: ARCs = actual risk calculations; DAT = direct 
antiblobulin test; IAT-Xh4 = indirect antiglobulin crossmatch; 
LISS = low-ionic-strength saline; PEG = polyethylene glycol; 
RBCW = red cells(s1. 
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relevance of these antibodies. Our 1992 data revealed that 
many examples of wanted agglutinins were from patients 
who were immunosuppressed, either by disease or treat- 
ment.’ Evidence for immune suppression was also found 
among patients with wanted agglutinins that were not de- 
tected by the gel test.3 Further, we are unaware of published 
reports of hemolytic transfusion reactions despite the wide- 
spread use of PEG and the gel test techniques, neither of 
which includes a separate reading for direct agglutination 
after 37°C incubation. Accordingly, we eliminated the 37°C 
reading from our LISS procedure. Before making such a 
procedural change, we used our 1992 data to calculate the 
associated risk. We compared this risk to other risks we are 
taking because of past changes made to our pretransfusion 
testing protocols-namely, elimination of the pretransfu- 
sion direct antiglobulin test (DAT)6 and elimination of the 
routine antiglobulin crossmatch (IAT-XM1.7 
In this report, we present the results of these compari- 
sons as well as the results of laboratory and clinical moni- 
tors designed to determine the effect of eliminating the 
370C reading on workload and patient care. 
MATERIALS AND METHODS 
Actual risk calculations (ARCS) used the equations n x 5 x 
percent antigen-positive x 0.34 or n x 5 x percent antigen- 
positive x 0.80. For both equations, n equals wanted anti- 
bodies missed, and 5 represents the average number at our 
institution of units given per patient transfused. The per- 
centage of antigen-positive units will vary with antibody 
specificity; the actual antigen frequencies used in the cal- 
culations were those corresponding to the antibodies 
missed following test elimination, as shown in our earlier 
s tudies . ’~~,~ Cases involving anti-D were excluded, because 
the patients would normally receive Rh-negative blood. The 
factor of 0.34 represents the percentage of “typed and 
screened” patients who are subsequently transfused at our 
institution and is used to evaluate the risk of eliminating the 
DAT and the 37°C reading. A factor of 0.80 represents the 
percentage of “crossmatched” patients at our institution 
who are transfused and is used to evaluate the risk of elimi- 
nating the routine IAT-XM. Both factors were obtained by 
review of activity reports for 1 month. All calculations were 
adjusted to current annual workload volumes of 30,000 
pretransfusion tests, 29,000 RBC transfusions, and 46,000 
crossmatches. Confidence intervals for proportions were 
calculated according to Gardner and Altman.8 
To monitor the impact of eliminating the 37°C reading 
on a prospective basis, we looked at the following informa- 
tion: l) antibody detection data, including the percentage 
of samples with a positive antibody screen and the nature 
of antibodies encountered in antibody identification stud- 
ies; 2) the number of patients who presented with newly 
formed antibodies of potential significance following recent 
transfusion, whether or not there was clinical evidence of 
a hemolytic transfusion reaction, and whether or not these 
antibodies would have been detected earlier if a 37°C read- 
ing had been included; and 3) the number of transfusion 
reactions reported by clinicians to the transfusion service 
and the outcome of our investigation into these reactions. 
The latter investigations were performed in accordance 
with requirements ofAmerican Association of Blood Banks 
Standard KZ.000.4 For patients with a positive DAT or free 
serum hemoglobin after transfusion, screening tests that in- 
cluded a reading for agglutination and hemolysis after 37°C 
incubation were performed on prereaction and postreaction 
samples. 
We gathered these data for two study periods, for 6 
months after elimination of the 37°C reading (1996-97) and 
for the same dates of the precedingyear (1995-961, when a 
37°C readingwas included in our test protocol. In addition, 
for patients with newly formed antibodies who had been 
transfused within the preceding month, we reviewed hema- 
tologic and biochemical data to obtain evidence for anti- 
body-mediated hemolysis. When previously submitted 
samples were available for testing, we performed a 37°C 
reading retrospectively using selected (antigen-negative; 
single- and double-dose-positive) reagent RBCs. 
For the 1995-96 study period, LISS tests for routine 
pretransfusion antibody detection were performed as de- 
scribed el~ewhere.~ These tests were modified for the 1996- 
97 study period by eliminating the centrifugation and read- 
ing for direct agglutination steps prior to washing for 
antiglobulin testing. Technologists were instructed to ob- 
serve the size of the centrifuged RBC button as an indica- 
tion of in vitro hemolysis. Reactions were graded as de- 
scribed el~ewhere.~ 
RESULTS 
The results ofARCs (Table 1) reveal that one patient per year 
is likelyreceiving 2 units of antigen-positive blood, because 
we no longer perform a pretransfusion DAT/autocontrol. 
The number of patients at risk is higher when an immedi- 
ate-spin crossmatch is used instead of an IAT-XM. Eight 
patients per year are likely exposed to 2 units of antigen- 
positive blood by the performance of an abbreviated 
crossmatch when unexpected antibodies are absent. By 
eliminating the 37°C reading, we calculate that nine pa- 
tients are placed at risk of receiving 1 or 2 units of incom- 
patible blood. When calculated in terms of the current num- 
ber of RBC units transfused annually (approx. 29,000), the 
risk of transfusing incompatible blood following test elimi- 
nation is approximately 1 in 13,000,l in 2,000, and 1 in 2,400 
units transfused for eliminating the DAT, IAT-XM, and 37°C 
reading, respectively. The cumulative risk associated with 
elimination of all three tests is approximately 1 in 1,000 
units transfused. 
Table 2 shows the differences in our activities for the 
two study periods. For the 6 months of 1996-97, our 
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I TABLE 1. Results of actual risk calculations* DATt IAT-XMS 37%6 Cumulative 
Patients at risk per year 1.1 7.75 8.45 17.3 
Incompatible units 2.25 14.34 12.25 28.84 
transfused per year [O.O, 5.11 [6.7, 21.3) [5.2, 18.81 [18.3, 39.41 
Incompatible units transfused 2.05 1.85 1.45 1.67 
per patient at r i sa  [O.O, 4.91 [O.O, 4.51 [O.O, 3.81 [O.O, 4.21 
Incompatible units per 1:12. 947 12, 032 1.2, 378 1:1, 010 
total transfused I“. 1:5.613111:4.211. 1:1.339111:5.404. 1:1.5241 I“. 1:6331 
[O.O, 3.2111 [2.3, 13.91 [2.7, 13.01 9.1, 25.51 
See text for details of calculations; all values corrected to current annual activities of 30,000 
pretransfusion tests, 29,000 RBC transfusions, and 46,000 crossmatches. 
t Data derived from Judd et aL6 In 29 months, seven potentially significant alloantibodies 
(3 anti-Kl, 3 anti-Jka, and 1 anti-E) were detected solely through evaluation of a positive 
DAT. * Data derived from Oberman and J ~ d d . ~  Over a 2-year period, 17 alloantibodies (5 anti-E, 
2 anti-Jka, 2 anti-K1, and 1 each of anti-C, -c, -Cw, -Fp, -Fe, -Jss, -V, and -WP) of poten- 
tial significance were missed in screening tests but detected by IAT-XM. 
5 37°C = reading for direct agglutination after 37°C incubation. Data derived from Judd et 
a1.l In 3 years, 73 potentially significant alloantibodies (44 anti-€, 21 anti-Kl, 4 anti-Jka, 3 
anti-cE, and 1 anti-C) were found in screening tests for unexpected antibodies solely by 
reading for direct agglutination after 37°C incubation; subsequently performed antiglobu- 
lin tests were nonreactive. 
II Figures in brackets represent lower and upper limits of 95% CIS for proportions. 
7 The percentage of incompatible units will vary with antibody specificity; the actual anti- 
gen frequencies used in the calculations were those corresponding to the antibodies missed 
following test elimination, as shown in our earlier s t u d i e ~ . ~ , ~ , ~  
** Undefined lower limit of CIS for incompatible units transfused is zero. 
TABLE 2. Antlbody detection (screening) and identification data before 
11995-961 and after (1996-971 elimination of the 37°C reading 
Screening tests Identification studies 
Positive tests’ Unwantedt Wanted* 
~ ~~ ~~ ~ 
Year Samples Total % Total % Total % 
1995-96 14.286 657 4.6 262 62 162 38 
[608, 7561s [4.3, 4.91 [231, 2921 [54.4, 69.21 [137, 1871 [32.4, 44.11 
(481, 5691 [3.2, 3.81 [234, 2981 [71.7, 91.01 [46, 761 [14.0, 23.31 
Number of positive screening tests does not equal total (wanted + unwanted) of antibody 
identification studies performed. Patients whose current antibody screen and crossmatch 
results are consistent with a recently performed identification study are not subjected to 
repeat investigation. 
t Number of identification studies that revealed findings not considered important with re- 
spect to transfusion of antigen-positive blood. Finding rarely requires selection of anti- 
gen-negative blood for transfusion. * Number of identification studies that revealed at least one antibody that is considered 
potentially significant with respect to transfusion of antigen-positive blood. Presence re- 
quires selection of antigen-negative units and an IAT-XM. 
Figures in brackets represent lower and upper limits of 95% CIS for proportions. 
1996-97 15,078 525 3.6 266 81 61 19 
There is no significant difference 
in the numbers of wanted antibodies 
encountered either before or after 
elimination of the 37°C reading (Table 
3). However, had we not performed a 
37°C reading in the 6-month period of 
1995-96, we would have missed 13 
“37°C only” antibodies of wanted 
specificities. This observation is con- 
sistent with our 1992 study, when we 
found approximately 25 patients with 
such antibodies per year.’ 
Table 3 also shows the unwanted 
antibodies detected in both study 
periods. There was a dramatic reduc- 
tion in the number of unwanted anti- 
bodies identified following elimina- 
tion of the 37°C reading; this reduction 
equates to some 200 samples annually. 
The second part of our study looked at 
patients in whom we detected newly 
formed antibodies of potential sig- 
nificance and who had been trans- 
fused within the preceding month. 
We found 31 such antibodies in 25 
patients in the 1996-97 study period. 
We evaluated these 25 patients for 
clinical evidence of immune hemoly- 
sis and compared our findings with 
those from 26 patients with newly 
formed antibodies encountered in 
the 1995-96 study period. While we 
found six cases of possible transfu- 
sion-related immune hemolysis in 
the 1996-97 study period versus four 
in 1995-96, this increase is not signifi- 
cant, given the total number of units 
transfused, which is in the order of 
15,000 units for each study period. 
For all 25 patients with newly 
formed antibodies of potential signifi- 
cance from the 1996-97 study period, 
we evaluated any available samples 
workload increase was such that we performed 5 percent 
more pretransfusion tests than in the same period of 1995- 
96. However, 4.6 percent of samples had positive tests for 
unexpected antibodies in 1995-96, compared to a 3.6-per- 
cent positive rate after elimination of the 37°C reading. 
Consequently, about 100 more samples required antibody 
identification studies in the 6 months of 1995-96 than in the 
same period of the following year. To a large extent, this dif- 
ference is a reflection of the number of unwanted antibod- 
ies that are no longer detected following elimination of the 
37°C reading. 
submitted prior to antibody ascertainment for direct agglu- 
tinating activity at 37°C. Retrospective testing of available, 
previously submitted samples from 17 patients revealed six 
antibodies reactive at 37°C (range f to 2+7. Onlyone ofthese 
(l+s anti-E) was associatedwith clinical evidence ofimmune- 
mediated hemolysis. 
Finally, in our review of transfusion reactions reported 
by clinicians, the number of reactions in the study periods did 
not differ significantly. No cases of transfusion-induced im- 
mune hemolysis were identified through our investigation of 
these reports. Moreover, we encountered no 37°C- only 
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TABLE 3. Specificities of antibodies detected before (1 995-96) and after 

















1996-97 Unwanted antibodies 1995-96 1996-97 
113 Cold alloantibodies 63 (19) 33 
73 Cold autoantibodies 55 (38) 4 
16 Warm autoantibodies 10 13 
12 Passive 11 4 
6 Other 23 (5) 7 
0 
46 
Total 262 (13) 266 Total 162 (62) 61 
Numbers in parentheses represent antibodies reactive solely as agglutinins at 37°C ; 
subsequently performed antiglobulin tests were nonreactive. 
agglutinins in prereaction or postreaction samples from pa- 
tients with a positive DAT or free serum hemoglobin after 
transfusion. 
DISCUSSION 
Approaches to pretransfusion testing have undergone con- 
siderable revision in the past two decades. Prompted by re- 
ductions in operating budgets for clinical laboratories that 
started with reforms to health-care reimbursement, prac- 
tices that yield a large number of unwanted positive tests 
are being abandoned, as are those generating data not ap- 
plied to patient management.I0 Past testing strategies are 
being replaced with streamlined protocols that facilitate 
timely, cost-effective provision of blood and blood prod- 
ucts. Nevertheless, while modifymg testing protocols, it is 
important to maintain quality patient care and adhere to 
regulatory requirements.’ 
Retrospective review of our experience with the pre- 
transfusion DAT led us to eliminate this test in June 1984.6 
At the same time, there was a national interest in eliminat- 
ing the IAT-XM for all patients except those known to have 
unexpected antibodies. We replaced the routine IAT-XM 
with an immediate-spin crossmatch in 1986. As shown in 
Table 1, each of these modifications to pretransfusion test- 
ing is associated with a risk of transfusing serologically in- 
compatible blood to a few patients per year. However, this 
risk has proven acceptable, given the benefits accrued by 
not having to investigate large numbers of unwanted pos- 
itive tests. 
In 1992, we reported the results of a 3-year retrospec- 
tive review of the incidence of potentially significant anti- 
bodies detected solely by reading for agglutination and 
hemolysis following 37°C incubation.’ This 1992 study was 
prompted by further fiscal pressures to streamline test pro- 
tocols and by the emergence of technologies that do not 
include a 37°C reading.5s’2*’3 Our 1992 study revealed that 
21.7 percent of antibodies detected solely by reading for 
agglutination after 37°C incubation have Rh, K, or Jk speci- 
ficity.‘ Because we encountered approximately 25 patients 
with such antibodies annually, we concluded that “elimina- 
tion of the 37°C reading for agglutination and hemolysis 
should not be undertaken lightly.” 
Moreover, we elected at that time to 
retain the 37°C reading as part of our 
screening procedure for unexpected 
antibodies. 
We revisited this 1992 decision 
following our gel test evaluation3 The 
gel test failed to detect, in addition to 
many examples of unwanted aggluti- 
nins, four examples of potentially sig- 
nificant alloagglutinins (3 K1 and 1 
Jka). All were from immunosup- 
pressed patients and were 
nonreactive by PEG and LISS-additive procedures. These 
findings, and the absence of reported hemolytic reactions 
associated with the widespread use of gel technology, 
prompted us to eliminate the 37°C reading from our 
pretransfusion antibody detection procedure. This modi- 
fication is permitted according to current American Asso- 
ciation of Blood Banks StandardsP We estimate the risk of 
transfusing serologically incompatible blood associated 
with elimination of the 37°C reading to be somewhat less 
(1:2400 vs. 1:2000 units transfused) than that associated 
with eliminating the routine IAT-XM. This risk analysis per- 
tains only to LISS tests performed in accordance with the 
procedure of Low and Messeter.2 Moreover, since the risks 
associated with elimination of the pretransfusion DAT/ 
autocontrol, IAT-XM, and the 37°C reading are cumulative, 
we calculate that approximately 1 in 1000 units transfused 
in our institution are incompatible because of to antibod- 
ies we no longer detect. 
The risk associated with other methods that do not in- 
clude a 37°C reading may or may not be comparable to our 
data. Alkhashan et al.14 performed LISS tests on 5027 
samples that were nonreactive by PEG-IAT and found four 
37+, IAT- Rh antibodies. These findings are in accord with 
the thirteen 37+, IAT- wanted antibodies we found among 
the 14,286 samples tested in the 1995-96 study period (see 
Tables 2 and 3). Further, Rolih et aI.l5 found that five of eight 
37+, IAT- LISS-reactive wanted antibodies, representing 0.2 
percent of 2460 antibody-containing samples tested, were 
nonreactive by a solid-phase adherence assay. In contrast, 
from a re-evaluation of our gel test data,3 four of six 37+, 
IAT- wanted antibodies detected by LISS were nonreactive 
by gel technology, representing 2.8 percent of 144 antibody- 
containing samples tested. However, our data are difficult 
to compare with those of Rolih et a1.15 because they evalu- 
ated only antibody-containing samples, the method by 
which their antibodies were ascertained is not defined, and 
their incidence of 37+, IAT- wanted antibodies (0.33% of 
2460 antibody-containing samples) was different from that 
of our 1992 study (2.9% of 3560 antibody-containing 
samples). 
Despite the above statistical differences, we conclude 
that the actual risk of eliminating the 37°C reading from 
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ant ibody detection tests is minimal, as evidenced by the 
fact that  we observed no significance increase i n  the inci- 
dence or severity of hemolytic transfusion reactions follow- 
ing such a modification t o  our LISS procedure. Elimination 
of the 37°C reading avoids discovery of a significant num- 
ber of  unwanted ant ibodies  that  otherwise would have 
prompted time-consuming, costly studies that  cause delay 
to patient care. In our institution, this equates  to a reduc- 
tion of antibody identification workload by 20 percent, or 
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